Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic visit, and (3) awareness/understanding of their health condition.
Participants who provide written informed consent will complete a brief survey during their clinic visit (about 5-7 minutes). The survey includes a standardized anxiety scale (GAD-7), visual analog scales (0-10) for anxiety before and after the visit, satisfaction, and disease awareness, as well as questions about AI/LLM knowledge and use. Treating clinicians will not have access to participants' survey responses, and participation will not affect clinical care.
The TALK-U study is a cross-sectional, observational survey conducted in the urology outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The primary exposure is self-reported AI/LLM knowledge and use for health information (e.g., whether participants have used ChatGPT or similar tools, frequency, awareness of AI, and purpose of use). The primary outcome is anxiety measured by GAD-7 at the time of the clinic encounter. Secondary outcomes include (i) anxiety assessed on a 0-10 visual analog scale before and after the visit, (ii) outpatient visit satisfaction (0-10 VAS), and (iii) perceived disease awareness/understanding (0-10 VAS).
Eligible adult first-time urology outpatients who can complete the survey independently and provide informed consent will be invited during a 2-month recruitment period. Analyses will compare outcomes between AI/LLM users and non-users and explore associations with age group (<40, 40-60, >60), education level, and urology subspecialty category. Data will be analyzed using appropriate parametric/nonparametric tests depending on distribution, with p < 0.05 considered statistically significant.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AI/LLM users | Participants who report prior use of AI chat tools based on large language models (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. | ||
| non AI/LLM users | Participants who report no prior use of AI/LLM chat tools (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Pre-visit Anxiety (VAS 0-10) | Self-rated anxiety on a 0-10 visual analog scale (VAS), where 0 indicates no anxiety and 10 indicates the highest possible anxiety. This measure reflects visit-related state anxiety prior to clinician encounter. | Day 0 (immediately before the outpatient visit) |
| Measure | Description | Time Frame |
|---|---|---|
| Post-visit Anxiety (VAS 0-10) | Self-rated anxiety on a 0-10 VAS (0 = none, 10 = highest). | Day 0 (immediately after the outpatient visit) |
| Visit Satisfaction (VAS 0-10) | Self-rated satisfaction with the outpatient visit on a 0-10 VAS (0 = not satisfied at all, 10 = maximum satisfaction). |
| Measure | Description | Time Frame |
|---|---|---|
| Baseline General Anxiety Symptoms (GAD-7 Total Score) | Total score on the 7-item GAD-7 questionnaire (range 0-21; higher scores indicate greater generalized anxiety symptoms). This measure will be used to account for baseline anxiety (trait-like symptoms) and to adjust analyses of VAS-based state anxiety out | Day 0 (at enrollment; prior to or during the clinic visit) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients (≥18 years) presenting for a first-time visit to the Urology Outpatient Clinic at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital will be invited to participate during a 2-month recruitment period. Participants who provide written informed consent and can complete a brief questionnaire independently will be enrolled. The study will include both sexes and a broad range of urologic presenting complaints.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tuncel Uzel, MD | Contact | +90 312 336 09 09 | 5622 | tunceluzelmd@gmail.com |
| Mehmet Duvarcı, MD | Contact | +90 312 336 09 09 | 5616 | mehmet_duvarci@hotmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital | Ankara | Yenimahalle/Ankara | 06200 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D017060 | Patient Satisfaction |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 0 (immediately after the outpatient visit) |
| Disease Awareness/Understanding (VAS 0-10) | Self-rated awareness/understanding of one's condition on a 0-10 VAS (0 = none, 10 = complete). | Day 0 (during the outpatient clinic visit) |